Lunch & Learn



Cannabis – What Does it Mean for your Practice?

September 25, 2019

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care

Presented in partnership by:





American Association of NURSE PRACTITIONERS[®]




Transforming Clinical Practices Initiative

Housekeeping Items

To **download materials**, go to the Handouts section on your GoToWebinar control panel.

To **ask a question**, type it into the Question pane in the GoToWebinar control panel and it will be relayed to the presenter.







Steps to Receive Free CE Credit

AANP will review attendance list after webinar is complete.

Participants who attend entire live presentation qualify for CE credit – 1.0 CE / 1.0 Pharm

- **REQUIRED:** attend at least **55 minutes** of presentation
- **REQUIRED:** access & connect to presentation slide-deck
- Phone-in-only participants **DO NOT** qualify

Participants who qualify for CE will receive a detailed email on how to obtain CE credit using the AANP CE Center.

Passcode and completion of an evaluation will be required to receive CE credit.

Questions can be directed to: calrich@aanp.org



National Investment in Quality Improvement

- Changes to the health care system are here
- Nurse practitioners (NPs) will play a key role during the critical transition from Feefor-Service to Value-Based Reimbursement
- NNCC and the AANP have partnered together to create the Nurse Practitioner Support & Alignment Network (NP SAN):
 - Prepare NPs for the upcoming changes to the health care system
 - Provide free continuing education & professional development centered around value-based health care practices
 - Offer key training opportunities that ready practices for Value-Based
 Reimbursement






Preparing NPs for Value-Based Reimbursement

What is the Quality Payment Program?

Began in 2017 as a result of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and requires CMS by law to implement an incentive program referred to as the *Quality Payment Program*, that provides for <u>two</u> participation tracks:









- Designed for individuals & small practices
- Four (4) performance areas
- Replaces all current incentive programs
- Exempt if practice DOES NOT meet low volume threshold.

- Higher risk model
- Risk is shared throughout the APM
- Number of acceptable payment models is limited
- Rules to being considered a qualified provider (QP)





Where Can I Go to Learn More?

- 1. CMS QPP website www.qpp.cms.gov
- 2. NPI Lookup for participation status https://qpp.cms.gov/participation-lookup
- 3. AANP https://www.aanp.org/legislation-regulation/federallegislation/macra-s-quality-payment-program







Cannabis: What Does it Mean for Your Practice?

Theresa Mallick-Searle, MS, RN-BC, ANP-BC Stanford Heath Care, Division Pain Medicine <u>Tmallick@stanfordhealthcare.org</u> @tmallic

in https://www.linkedin.com/in/theresa-mallick-searle



Disclosures

Speakers bureau: Amgen & Lilly Pharmaceuticals

Any unlabeled/unapproved uses of drugs or products referenced will be disclosed.

Covering a very LARGE topic in a short amount of time.

Learning Objectives

• Define the endocannabinoid system.

• Discuss evidence for cannabinoids in pain management.

• Review practical clinical basics & safety considerations.

Is this really a big deal?

- Most states (Guam & DC) in the US that have legislation allowing for the medicinal use of cannabinoids.
- Federally illegal! Major confusion?!
- Canada \rightarrow Cannabis Act
- $UK \rightarrow Legalize medicinal marijuana$
- FDA 2018 approved EPIDIOLEX® (cannabidiol) oral solution, schedule V.
- Global financial impact

Is this really a big deal?

Map shows current state laws and recently-approved ballot measures legalizing marijuana for medical or recreational purposes.

No doctor's recommendation required Doctor's recommendation required Limited THC content Prohibited

Information is current as of January 1, 2019

https://en.wikipedia.org/wiki/Medical_cannabis_in_the_United_States

Background

• USP 1850-1942

 1930s U.S. Federal Bureau of Narcotics "marijuana is a gate-way drug to narcotics addiction"

• 1937 Marijuana Tax Act

• The Controlled Substances Act of 1970

• Agriculture Act 2014/Hemp Farming Act 2018





Endocannabinoid System


Endogenous - homeostatic regulatory system inherited by all mammals.

Includes:

- ➤ CB1 & CB2 receptor sites
 - {CBx & VR1 receptor sites}
- Endocannabinoids
 - Anandamide
 - > 2-arachidonylglycerol (2AG)
 - Nolan ether
 - Virodhamine
 - > NADA
- Synthesizing & degrading enzymes

- Cognition & memory
- Appetite & digestion
- Stress response
- Inflammation
- Motor celaxol
- Sleep eat
- Explorstieep social behavitorgetanxiety
- Immune/Etectorine function
- Autonomic nervous system
- Antinociception

Endogenous Cannabinoid System



Clinical Endocannabinoid Deficiency

Ethan Russo, MD (2004/2016)

- ➤ The ECS theory of disease.
- Lack of sufficient endocannabinoids/ dysregulation of the ECS.
- Result in higher susceptibility (fibromyalgia, irritable bowel syndrome, depression, anxiety, migraine).
- Phytocannabinoids (THC, CBD) can bind to the cannabinoid receptor sites (CB1, CB2), and mimic the physiological processes seen with binding of the endocannabinoids.



What is cannabis sativa (aka marijuana)?

It is a Plant w/over 400 different chemicals:

- ≻ >60 types of cannabinoids
 - delta-9-tetrahydrocannabinol (THC)
 - Cannabidiol (CBD)
 - Cannabinol (CBN)
 - Cannabichromene (CBC)
 - Cannabigerol (CBG)
 - Tetrahydrocannabivarin (THCV)
- Flavonoids, Terpenes, Terpenoids
- Fungus? Bacteria? Pesticides?





Byproducts of manufacturing (solvents, heavy metals)

Research

- Center for Medicinal Cannabis Research
- National Center for Natural Products Research (NCNPR) at the University of Mississippi
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health (NIH)
- Canadian Institutes of Health Research
- Canadian Consortium for the Investigation of Cannabinoids (CCIC)

Europe

- The Medicinal Cannabis Research Foundation (MCRF): UK
- o Spain, Germany, Italy
- ICRS: http:// www.cannabinoidsociety.org



https://clinicaltrials.gov/

Original Investigation

Cannabinoids for Medical Use A Systematic Review and Meta-analysis

Penny F. Whiting, PhD; Robert F. Wolff, MD; Sohan Deshpande, MSc; Marcello Di Nisio, PhD; Steven Duffy, PgD; Adrian V. Hernandez, MD, PhD; J. Christiaan Keurentjes, MD, PhD; Shona Lang, PhD; Kate Misso, MSc; Steve Ryder, MSc; Simone Schmidlkofer, MSc; Marie Westwood, PhD; Jos Kleijnen, MD, PhD

Moderate-quality evidence support use of cannabinoids in chronic pain & spasticity.

Low-quality evidence: CINV, HIV weight loss, insomnia, Tourette's.

Use of cannabinoids were associated with increased risk of short-term adverse effects. META-ANALYSIS

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis

Howard Meng, MD,* Bradley Johnston, PhD,†‡§|| Marina Englesakis, MLIS,¶ Dwight E. Moulin, MD,# and Anuj Bhatia, MBBS, MD, FRCPC, FRCA, FFPMRCA, FIPP, EDRA, CIPS*

- Selective cannabinoids provided a small benefit in chronic neuropathic pain.
- High degree of heterogeneity amongst included publications.
- Need for additional: well designed, large, RCT to better assess dosage/duration/effects on physical & psychological function.



Cannabis-based medicines for chronic neuropathic pain in adults (Review) 2018

High-quality evidence is lacking.

All cannabis-based medicine pooled together were better than placebo:

- Reducing pain intensity
- Reports of moderate pain relief
- Improvement in sleep
- Improvement in psychological distress
- ➢ Global improvement



Cannabis-based medicines for chronic neuropathic pain in adults (Review) 2018


Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W

All cannabis-based medicine pooled together were NO better than placebo:

- Improving health-related QOL
- Stopping medication because it was not effective
- Frequency of serious side effects

More people reported sleepiness, dizziness, cognitive problems and dropped out of studies because of side effects with all cannabis-based medicines pooled together versus placebo. The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research (2017)

- In adults with chemotherapy induced N/V, oral cannabinoids are effective antiemetics.
- Adults with chronic pain are more likely to experience clinically significant pain relief.
- Adults with MS related spasticity reported improvement of spasticity symptoms.



Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2017. The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research. Washington, DC: The National Academies Press. "Used with permission"

The National Academies of SCIENCES • ENGINEERING • MEDICINE

Is Cannabis a Rational Solution to the Opioid Crisis?

Pro/Advocates

- Excellent alternative, less addictive, less likely to result in death.
- "Alternatives to Opioids Act of 2018" Illinois
- NY "adding any condition for which an opioid could be prescribed as a qualifying condition for medical marijuana."
- The National Institutes of Health recently awarded a 5-year \$3.8 million grant. [Albert Einstein College of Medicine - Chinazo Cunningham, M.D.]

Con/Critics

- Substitution of one addictive substance for another.
- Side effects under recognized (e.g. psychosis).
- Evidence hasn't proven benefit for pain.

Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis (2017)

Purpose: Determine the opioid-sparing potential of cannabinoids. Results: Studies included in qualitative synthesis (n = 28)

- Median effective dose of morphine administered in combination with delta-9-THC is 3.6 times lower than the of morphine alone.
- Codeine administered in combination with delta-9-THC was 9.5 times lower than of codeine alone.

Neuropsychopharmacology. 2017 Aug;42(9):1752-1765.

Research

Original Investigation

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010

Marcus A. Bachhuber, MD; Brendan Saloner, PhD; Chinazo O. Cunningham, MD, MS; Colleen L. Barry, PhD, MPP

The enactment of statewide medicinal marijuana laws is associated with significantly lower state-level opioid overdose mortality rates, according to data published in August 2014 in JAMA Internal Medicine.

Researchers reported, "States with medical cannabis laws had a 24.8 percent lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws."

I know nothing about cannabis!



Important Talking Points

- > Encourage open/non-judgmental dialogue.
- > Driving "under the influence".
- Recommend obtaining medical marijuana card issued by state.
- > Traveling considerations.
- > Share the extend of the research that is known.
- Provide website resources.
- Discuss drug to plant interactions, side effects, risk of addiction.
- Recommend products & dispensaries?

Mental Health

Cannabinoids (THC) appear to effect the same reward system as alcohol, cocaine, opioids.

Evidence for cannabis dependence from epidemiological studies (*Miller & Plant 1996; Malhotra & Biswas 2006*).

- irritability, anxiety, disturbed sleep, craving

Mental wellness

- Worsen sub-clinical, stable mental illness
- Effective motivation
- Psychosis in genetically susceptable individuals

Tolerance & Adverse Effects (AEs)

Tolerance

- Mood, sleep
- Psychomotor performance
- Arterial pressure
- Antiemetic properties
- Common AEs
 - Anticholinergic effects (dry mouth, blurry vision, urinary retention, tachycardia, constipation, hypertension).
 - CNS effects (ataxia, cognitive dysfunction, hallucination).

Cannabis Hyperemesis Syndrome

Pharmacokinetics: delta-9-tetrahydrocannabinol

- THC psychoactive cannabinoid
- Highly lipophilic
- Rapidly absorbed through lungs after inhalation, quickly reaching high serum concentration
- Systemic bioavailability is ~23-27% for daily users, ~10-14% occasional users
- > Extensive liver (first pass) metabolism; cytochrome P450
- > >65% excreted in the feces, ~20% urine
- > t1/2 occasional users is 1-2 days, daily users up to 2 weeks

Stirring the Pot: Potential Drug Interactions

- CYP450 Enzymes: 1A2, 3A4, 2C9, 2C19.
- CNS depressants, antidepressants, central nervous system drugs – potentiate effects of THC.
- Any medications that are metabolized through the same pathways could result in less or more of the drug's effects.
- For scientific reviews: Drug Metabolism Reviews.
- Epocrates is a good quick reference for cannabidiol and synthetic THC.

Oral versus Inhaled

	INHALED	ORALLY INGESTED
Peak Blood Levels (min)	3-10	60-120
Bioavailability (%)	10-40	<15
Time to peak psychoactive activity (min)	20	120-240

Cannabidiol (CBD)

Defining Terms:

- > CBD from Hemp (\uparrow contaminants, \downarrow THC)
- CBD from cannabis sativa (↑THC, ↑purity)
- Hemp Oil (seeds of hemp plant, no CBD, no THC, +essential fatty acids, +omega three)

Research:

- Epidiolex®
- Other preliminary research included studies of anxiety, cognition, movement disorders, and pain (anti-inflammatory).
- Efficacy most antidotal (discuss current animal studies).

Safety: Dosing toxicity? Anti-inflammatory effects? CYP450 metabolism.

Side Effects: Fatigue, diarrhea, changes of appetite/weight, dry mouth. Transaminase elevations (reported in Epidiolex studies).



- **1.** Decide Why You Want to Use CBD, and in What Form
- **2.** Consider How Much THC the Product Contains
- **3.** For Products From Hemp, Find Where It Was Grown
- 4. Ask for Test Results
- **5.** Look for Products That List the CBD Amount
- 6. Know What Other Terms on the Label May Mean
- 7. Avoid Products That Make Sweeping Health Claims
- 8. Watch Out for Vaping Products With Propylene Glycol

https://www.consumerreports.org/marijuana/how-to-shop-for-cbd/

Recommend only products that are properly labeled.

- Label information should include the ingredients and the milligrams of each cannabinoid per dose.
- Recommend only products from companies that test for potency, pesticides, mold, and bacteria.
- Mindful of byproducts of production (e.g. solvents).

	Afgi	hai	ni X	Ibaceutical™ F Sour Diesel Tested C November 1	India Ca Sun Gra	an Orp
Total Aerobic Count GOLD Total Entero-bacteria GOLD			Total Yeast & Mold	GOLD PASS		
			Pestodes Screen			
At-THC Max:	18.	-	16 96	Sum of Top Terpenes	22.5	mg/g
A*-THC	0.3	25	%	β-Caryophyliene	7.5	ma/g
CBD Max:	0.3	35	.96	Myrcene	3.5	mo/g
CBDA	0.0	80	-96	Limonene	3.2	mp/g
CBO	0.2	27	36	a-Humulene	2.8	mp/g
CBG Max	1.8	32	. 16	g-Pinene	2.6	mo/g
Ƽ-THCVA	0.1	13	-96	B-Pinene	1.5	mo/g
CBN	N	D	96	Germacrene B (t).	.1.5	ma/a

The Vape Pen

 Avoid with products that contain propylene glycol (solvent).



Mike Moffitt, SFGATE | on August 16, 2019



 Propylene glycol can degrade to formaldehyde.

• Recommend vape pens that contain "solvent-free oils".



	 K 3
Photo: Contributed Photo	
Hote: Contributed I Hote	K 7

Hemp CBD Scorecard: An Evaluation of Hemp CBD Producers



Center for Food Safety (CFS) is a national nonprofit public interest and environmental advocacy organization

https://www.centerforfoo dsafety.org/reports/5719 /hemp-cbd-scorecard-anevaluation-of-hemp-cbdproducers

Regardless of the specific physiological system, the effects of cannabis are dependent on many factors:

Dose, variety

> Route (Inhalation, oral, transmucosal, transdermal, topical)

➤ Timing

General health (medical co-morbidities), Age

- Use of other substances/medications
- Chronic user of cannabis versus naive

https://www.colorado.gov/pacific/sites/default/files/MED%20Equivalency_Final%2008102015.pdf

Average adult dosing of THC:

Cannabis-naïve individuals	2.5-5 mg
Daily - weekly users	10-20 mg
≻Daily+	25 mg+

Doses exceeding 20–30 mg/day may increase adverse events or induce tolerance without improving efficacy.

https://www.leafly.com/news/cannabis-101/cannabis-edibles-dosage-guide-chart

MacCallum & Russo, 2018

Average adult dosing of CBD:

> 300-1500 mg/day

https://www.webmd.com/vitamins/ai/ingredientmono-1439/cannabidiol

Sativex® (1:1 THC/CBD): Spasticity due to multiple sclerosis.

>2.7mg/2.5mg BID

(max 32.4mg/30mg/day)

https://www.medicines.org.uk/emc/product/602

Epidiolex® (CBD): Seizures (Dravet/Lennox-Gastaut)

≻5 mg/kg oral BID

(max 20 mg/kg/day)

<u>https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pd</u>

LACK OF STARDIZATION MAKES DOSING A CHALLENGE FOR PATIENTS & PRACTITIONERS

Overconsumption:

- Re-dosing too soon
- Delayed on-set with oral dosing (>120 minutes)
- Hostile behavior/erratic speech/mild psychosis

The L.E.S.S. Method: A measured approach to oral cannabis dosing

Start Low

Establish potency

≻Go **s**low

Supplement as needed

(Erowid & Erowid, 2011)

Tips

➤ Familiarize yourself with

- THC, CBD dosing.
- drug : drug (plant) interactions, side effects, withdrawal.
- local dispensaries and counsel patient to accordingly.

- ➤Consider The Treatment Agreement.
- ➤Continue to remember Federally illegal.
- >Mindful of addiction, abuse, mental health issues.

Final Takeaways

Cannabinoids emerging as valid option for refractory chronic pain management.

Innovative solutions to opioid crises needed.

Cannabinoid-opioid synergy deserves attention.

Clinical trials challenging to design but necessary to conduct.

≻ Can no longer refuse to discuss.





Resources

Dispensary Information: Voluntary Patient Focused Certification

http://patientfocusedcertification.org/certification/

Addresses product & distribution safety

Based on quality standards for medical cannabis products and businesses issued by the American Herbal Products Association (AHPA) and the American Herbal Pharmacopoeia (AHP) Cannabis monograph

http://camcd-acdcm.ca/

Resources

Canadian Consortium for the Investigation of Cannabinoids (CCIC): <u>www.ccic.net</u>

- Accredited cannabinoid education (ACE) programs
- Informed by needs assessments, expert faculty

International Cannabinoid Research Society (ICRS): <u>www.icrs2014.org</u>

International Association for Cannabinoid Medicine (IACM): www.cannabis-med.org

University of Washington & Alcohol and Drug Abuse Institute (ADAI)

http://adai.uw.edu/mcacp/index.htm

Society of Cannabis Clinicians: www.cannabisclinicians.org

Physician/Clinician Training

New York:

https://www.health.ny.gov/regulations/medical_marijuana/practitioner/ Florida:

http://www.flhealthsource.gov/ommu/physician_requirements

All licensed MDs/DOs – some states require specialty practice (e.g. pain management, palliative care, etc.)


MS in Medical Cannabis Science and Therapeutics at the School of Pharmacy should contact <u>msmedicalcannabis@rx.umaryland.edu</u>

NPs: OR, WA, NY, MA, NM, ME, NJ

http://adai.uw.edu/mcacp/index.htm

Thank You

Questions?



- 1. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011 Dec;90(6):844-51.
- 2. Aggarwal SK et al. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013. Feb;29(2):162-71.
- 3. Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Metaanalysis of Individual Patient Data. J Pain. 2015 Dec;16(12):1221-32.
- 4. Blake DR et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50–2.
- 5. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85.
- 6. Carter G, Weydt P, Kyashna- Tocha M, Abrams D. Medicinal Cannabis: Rational guidelines for dosing. *IDrugs: The Investigational Drugs Journal* 2004;7(5):464-70.
- 7. Croxford J. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17(3):179-202.
- 8. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploration. *Pharmacol Res* 2009;60(2):77-84.
- 9. Erowid E, Erowid F. "The L.E.S.S. Method: A Measured Approach to Oral Cannabis." *Erowid Extracts* Nov 2011;21:6-9.


- 10. Fine PG et al. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013 Oct 29;4(4):e0022.
- 11. Guindon J & Hohmann A. The endocannabinoid system and pain. *CNS Neurol Disord Drug Targets* 2009;8:403-421.
- 12. Hazekamp A, & Fischedick J. Cannabis from cultivar to chemovar. *Drug Testing and Analysis* 2012;4(special issue):660-667.
- 13. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA. 2015 Jun 23-30;313(24):2474-83.
- 14. Hua T, Vemuri K, Pu M, et al. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell 2016;167:750–762.
- **15**. Janero D & Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experieince, and translational prognosis. *Expert Opinion On Emerging Drugs* 2009;14(1):43-65.
- 16. Johnson JR et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79.
- 17. Kahan M et al. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014 Dec;60(12):1083-1090.
- 18. Lynch ME et al. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011 Nov;72(5):735-44.

- 19. MacCallum CA & Russo EB. Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine* 2018;49:12–19.
- 20. Malhotra A & Biswas P. Cannabis Use and Performance in Adolescents. *Journal of Indian Association for Child and Adolescent Mental Health* 2006;2(2):59-67.
- 21. Martin-Sanchez E et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009Nov;10(8):1353-68.
- 22. McPartland J. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system. *Brain Res Rev* 2004;45(1):18-29.
- 23. Melton S. Stirring the Pot: Potential Drug Interactions with Marijuana. ...
- 24. Miller P & Plant M. Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom. BMJ 1996 Aug 17;313(7054):394-7.
- 25. Moulin D et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014 Nov-Dec; 19(6):328-35.
- 26. Murry R, Quigley H, Quattrone D, et al. Traditional marijuana, high-potency cannabinoid and synthetic cannabinoids: increasing risk for psychosis. *World Psychiatry* 2016;15(3):195-204.
- 27. Nugent S, Morasco B, O'Neil M, et al. The effects of cannabis among adults with chronic pain and an overview of general harms. *Annals of Internal Medicine* 2017;167(5):319-332.
- 28. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713-24.

- 28. Pacher P, Batkai S, & Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Diabetes* 2006;55(3):389-462.
- 29. Price M, Baillie G, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. *Mol Pharmacol* 2005;68(5):1484-95.
- 30. Rani Sagar D, Burston JJ, Woodhams SG, Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3300-11.
- **31**. Rom S & Persidsky Y. Cannabinoid receptor 2: Potential role in immunomodulation and neuroimflammation. J *Neuroimmune Pharmacol* 2013;8:608-620.
- 32. Russo E. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment resistant conditions? *Neuroendocrinol Lett* 2004;25(1-2):31-39.
- 33. Russo E. Cannabinoids in the management of difficult to treat pain. *Ther Clin Risk Manag* 2008;4(1):245-259.
- 34. Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. J Med Toxicol. 2017, 13(1):71-87.
- 35. Walsh Z, Gonzalez R, Crosby K, et al. Medical cannabis and mental health: a guided systematic review. *Clin Psychol Rev* 2017;51:15-29.
- 36. Wilkerson J & Milligan E. The central role of glia in pathological pain and the potential of targeting the cannabinoid 2 receptor for pain relief. *ISRN Anesthesiol* 539894: 2011

Any Questions??

Please **submit questions** via the question pane in your GoToWebinar control panel or raise your hand to ask a question.







Other QPP or NP SAN Questions?

For more information on the **QPP** or the **Nurse Practitioner Support and Alignment Network (NP SAN)**:

- Email Casey Alrich at calrich@nncc.us
- Visit us online at https://www.aanp.org/practice/np-san
- Stay up to date on the latest CE opportunities: http://bit.ly/NPSAN_subscribe





NP SAN Member Survey Results: Your Voice Heard and Next Steps



October 23, 2019, 12:00 pm ET

Register Here



